Monopar Therapeutics, Inc.
(NASDAQ : MNPR)

( )
MNPR After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
AMGNAmgen, Inc. 0.94%245.371.5%$928.59m
MRNAModerna, Inc. 0.71%144.270.0%$827.22m
REGNRegeneron Pharmaceuticals, Inc. 0.84%612.492.6%$518.34m
GILDGilead Sciences, Inc. 0.80%63.081.0%$507.58m
VRTXVertex Pharmaceuticals, Inc. 3.19%292.551.9%$481.51m
NVAXNovavax, Inc. -0.27%51.6775.7%$417.87m
ILMNIllumina, Inc. 0.20%193.933.3%$327.84m
BIIBBiogen, Inc. 0.26%211.931.8%$220.55m
SNSSSunesis Pharmaceuticals, Inc. 9.63%2.960.7%$206.91m
CRSPCRISPR Therapeutics AG 2.78%66.960.6%$167.22m
BNTXBioNTech SE 1.32%134.040.0%$150.84m
BMRNBioMarin Pharmaceutical, Inc. 2.72%86.854.2%$114.78m
EXASEXACT Sciences Corp. 6.89%45.1517.7%$99.68m
TECHBio-Techne Corp. 2.16%352.764.5%$94.64m
IOVAIovance Biotherapeutics, Inc. 0.19%10.350.0%$93.26m

Company Profile

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline includes Validive, Camsirubicin and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.